AAD 2019—Hair loss: a potential for platelet-rich plasma therapy


  • Marielle Fares, Pharm.D.
  • Conference Reports
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • A prospective randomized trial indicated that treatment of androgenic alopecia (AGA) with platelet-rich plasma (PRP) products is safe and effective among both men and women

Why this matters

  • Previous clinical studies have pointed to the safety and effectiveness of PRP in the treatment of AGA.

Key results

  • At 6 months, both patient groups studied had a statistically significant increase in hair count (P<.001 and a higher more rapid response was seen in group>
  • Patients in group 1 received 3 subdermal PRP injections per month and a booster dose after 3 months.
  • Patients in group 2 received 2 subdermal PRP injections every 3 months.
  • Folliscope hair count increased significantly (29.6±13.6 in group 1 vs 7.2±10.4 in group 2; P<.001 in both groups.>
  • Shaft caliber increased significantly in both groups with no significant difference between groups.
  • Survey results showed patients had high satisfaction with treatment (82% of patients were satisfied or highly satisfied).
  • Treatment was well-tolerated, with a mean pain score of 2.1.

Study design

  • 40 patients with moderate AGA were analyzed in a prospective randomized single-blinded trial.
  • Patients were randomly assigned according to 2 treatment protocols (group 1 received 3 injections per month followed by a booster dose at 3 months, and group 2 received 2 injections every 3 months).
  • Funding: Eclipse Aesthetics, LLC.

Limitations

  • Small number of patients.